Sunvozertinib

CAS No. 2370013-12-8

Sunvozertinib( —— )

Catalog No. M35766 CAS No. 2370013-12-8

Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 46 Get Quote
5MG 55 Get Quote
10MG 78 Get Quote
25MG 122 Get Quote
50MG 205 Get Quote
100MG 353 Get Quote
500MG 1314 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Sunvozertinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor.
  • Description
    Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR | BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2370013-12-8
  • Formula Weight
    584.08
  • Molecular Formula
    C29H35ClFN7O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (85.60 mM; Ultrasonic (<80°C)
  • SMILES
    COc1cc(N2CC[C@H](C2)N(C)C)c(NC(=O)C=C)cc1Nc1nccc(Nc2cc(Cl)c(F)cc2C(C)(C)O)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.
molnova catalog
related products
  • EGFR/ErbB2 Inhibitor

    EGFR/ErbB2 Inhibitor is a cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively)

  • Gefitinib

    A potent, selective, orally active EGFR inhibitor with IC50 of 23 nM; inhibits EGF-stimulated proliferation of KB cells with IC50 of 80 nM.

  • Lazertinib

    Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.